Clavis obtains funding for its lipid-based programme

Friday 26 June 2009

Location

Norway

Clavis Pharma ASA, a Norwegian company that specialises in lipid-based delivery of pharmaceutical agents, achieved an endorsement of its technology with a placement of new shares worth NOK 129 million (€14.3 million).

Full text available to subscribers only. Click here for information on subscribing to MedNous.